Piper Jaffray Keeps Intersect ENT (NASDAQ:XENT) As a “Buy”; They Now Have a TP Of $35.0000

Intersect ENT, Inc. (NASDAQ:XENT) Logo

Intersect ENT (NASDAQ:XENT) Rating Reaffirmed

New York: In an analyst note made public on Wednesday morning, Piper Jaffray kept their “Buy” rating on Intersect ENT (NASDAQ:XENT) shares. They now have a $35.0000 target on the company. Piper Jaffray’s target means a potential upside of 16.63 % from the company’s previous close.

The stock increased 0.44% or $0.13 during the last trading session, reaching $30.01. About 236,356 shares traded. Intersect ENT, Inc. (NASDAQ:XENT) has declined 9.19% since December 2, 2017 and is downtrending. It has underperformed by 24.81% the S&P500.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company has market cap of $916.97 million. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It currently has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

More notable recent Intersect ENT, Inc. (NASDAQ:XENT) news were published by: Nasdaq.com which released: “Notable Friday Option Activity: XENT, KMX, AGN – Nasdaq” on September 21, 2018, also Nasdaq.com with their article: “Noteworthy Wednesday Option Activity: WBA, AKAO, XENT – Nasdaq” published on June 20, 2018, Seekingalpha.com published: “Pooled data show treatment value of Intersect ENT sinus implants – Seeking Alpha” on November 15, 2018. More interesting news about Intersect ENT, Inc. (NASDAQ:XENT) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth – GlobeNewswire” published on October 25, 2018 as well as Streetinsider.com‘s news article titled: “JPMorgan Says CMS Decision on Sinuva is Likely an Error Following Discussion with Management (XENT) – StreetInsider.com” with publication date: May 07, 2018.

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.